Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829790 · ClinicalTrials.gov registry record · Phase 1
Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00829790: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00829790 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00829790, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of this study was to compare the rate of absorption and the oral bioavailability of a test formulation of doxycycline monohydrate 1 x 25 mg (5mL) oral suspension manufactured by IVAX Pharmaceuticals, Inc. and distributed by TEVA Pharmaceuticals USA to an equivalent oral dose of the commercially available reference product, Vibramycin Monohydrate® manufactured by Pfizer, Inc. Following an overnight fast of at least 10 hours, subjects consumed a standard high-calorie. high-fat breakfast meal. This standard breakfast meal began 30 minutes prior to each dose.
Interventions
- DRUG Doxycycline Monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-10 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829790
The ClinicalTrials.gov registry entry for NCT00829790 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doxycycline Monohydrate is the first listed.
NCT00829790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829790 about?
NCT00829790 is a clinical study titled "Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions". The objective of this study was to compare the rate of absorption and the oral bioavailability of a test formulation of doxycycline monohydrate 1 x 25 mg (5mL) oral suspension manufactured by IVAX Pharmaceuticals, Inc. and distributed by TEVA Pharmaceuticals USA to an equivalent oral dose of the com...
What is the current status of trial NCT00829790?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2006-10. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00829790?
The interventions under investigation include: Doxycycline Monohydrate (DRUG).
Who is sponsoring clinical trial NCT00829790?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.